Background on Pfizer and its Relevance
Pfizer, a leading global pharmaceutical company based in the United States, is currently one of the top 20 countries for its clinical trials. The company aims to elevate its position by accelerating the timeline for these crucial research activities.
Gabriela Dávila’s Statement and Opportunities for Improvement
Gabriela Dávila, the regional director of clinical research for Pfizer in Europe, Canada, and Latin America, emphasized the need for legal certainty, continuous improvement, simplification, and digitalization in Mexico’s clinical research sector. She highlighted areas for improvement, such as reducing regulatory processing times that currently take between 300 to 400 days.
Potential Impact of Faster Approvals
Dávila stated that if Mexico manages to achieve competitive approval timelines of 45 to 90 days for protocol approvals and importation of supplies, the country could rank among the top global clinical research markets. This would enable Pfizer to advance its growth objectives.
Current Clinical Trials in Mexico
Pfizer currently conducts 25 active clinical trials in Mexico, with an additional 23 on the horizon. The company anticipates closing the year with up to 48 protocols across various research stages in different therapeutic areas, including oncology, inflammation, immunology, infectious diseases, and internal medicine.
Investment in Mexico’s Clinical Research
Over the past four years, Pfizer has invested more than $64 million in clinical research within Mexico. These investments have generated significant economic impact and created both direct and indirect employment opportunities.
Achieving the Plan México Goal
Dávila believes that with the collaboration of public and private institutions, medical professionals, patients, and a robust research ecosystem, Mexico can meet the Plan México goal of attracting $2 billion in clinical research investments.
Required Improvements
To reach this goal, Mexico needs to enhance its infrastructure, streamline processes, eliminate delays, and redundancies in regulatory procedures. This can be accomplished through teamwork and shared commitment to clinical research.
Key Questions and Answers
- What is Pfizer’s current position in clinical trials? Pfizer is among the top 20 countries for its clinical trials.
- What improvements does Pfizer seek in Mexico’s clinical research sector? Pfizer seeks legal certainty, continuous improvement, simplification, and digitalization in Mexico’s clinical research sector.
- What are the potential benefits of faster approval timelines for clinical trials in Mexico? Faster approval timelines could position Mexico among the top global clinical research markets, enabling Pfizer to advance its growth objectives.
- How many clinical trials is Pfizer currently conducting in Mexico? Pfizer has 25 active clinical trials and plans to initiate 23 more, aiming for up to 48 protocols by year’s end.
- What therapeutic areas are Pfizer’s clinical trials focused on in Mexico? Pfizer’s clinical trials in Mexico focus on oncology, inflammation, immunology, infectious diseases, and internal medicine.
- How much has Pfizer invested in clinical research in Mexico over the past four years? Pfizer has invested more than $64 million in clinical research within Mexico over the past four years.
- What is Plan México, and what is its goal regarding clinical research? Plan México aims to attract $2 billion in clinical research investments.
- What steps are necessary for Mexico to meet Plan México’s goal? Mexico needs to enhance its infrastructure, streamline processes, eliminate delays, and redundancies in regulatory procedures through teamwork and shared commitment to clinical research.
